Monte Rosa Therapeutics, Inc. (GLUE)
- Previous Close
5.45 - Open
5.37 - Bid 5.27 x 100
- Ask 5.35 x 200
- Day's Range
5.29 - 5.49 - 52 Week Range
2.44 - 8.84 - Volume
86,169 - Avg. Volume
135,073 - Market Cap (intraday)
267.321M - Beta (5Y Monthly) 1.45
- PE Ratio (TTM)
-- - EPS (TTM)
-2.63 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
16.83
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
www.monterosatx.comRecent News: GLUE
Performance Overview: GLUE
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GLUE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GLUE
Valuation Measures
Market Cap
267.32M
Enterprise Value
80.95M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.49
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.59
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-27.72%
Return on Equity (ttm)
-60.07%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-135.35M
Diluted EPS (ttm)
-2.63
Balance Sheet and Cash Flow
Total Cash (mrq)
232.41M
Total Debt/Equity (mrq)
25.68%
Levered Free Cash Flow (ttm)
-55.47M